

## AMENDMENTS TO THE CLAIMS

Please update the claims in accordance with the claim listing found below.

### CLAIMS:

We claim:

1-11. (Canceled)

12. (Currently amended) An interfering ribonucleic acid (iRNA) oligonucleotide comprising from 15 to 60 nucleotides, which are complementary to nucleotides of a corresponding portion of the sequence SEQ ID No. 21 and which inhibits the expression of OB-RGRP.

13. (Original) The oligonucleotide as claimed in claim 12, which is a double-stranded RNA.

14. (Currently amended) A vector ~~expressing an~~ incorporating the oligonucleotide as claimed in one of claims 12 or 13.

15. (Currently amended) A cell containing a the vector as claimed in ~~either of claims claim 13 and 14.~~

16. (Canceled)

17. (Currently Amended) A ~~pharmaceutical~~ composition containing ~~a pharmacologically active amount of an~~ the oligonucleotide, as claimed in one of claims 12 or 13 and pharmaceutically acceptable excipients.

18-46. (Canceled)

47. (Currently amended) A ~~pharmaceutical~~ composition containing ~~a pharmacologically active amount of a~~ vector as claimed in claim 14 and ~~pharmaceutically~~ acceptable excipients.

48. (Currently amended) A ~~pharmaceutical composition~~ containing ~~a pharmacologically active amount of a~~ cell as claimed in claim 15 and ~~pharmaceutically~~ acceptable excipients.